Yongchao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yongchao Wang has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Zhenzhen Chen
School of Life Sciences, Zhengzhou University, Zhengzhou, China
5 shared publications Zimai Liu
School of Life Sciences, Zhengzhou University, Zhengzhou, China
5 shared publicationsJiao Lu
School of Life Sciences, Zhengzhou University, Zhengzhou, China
4 shared publicationsKai Li
School of Life Sciences, Zhengzhou University, Zhengzhou, China
4 shared publicationsPingping Zhu
School of Life Sciences, Zhengzhou University, Zhengzhou, China
4 shared publicationsZixian Wu
School of Life Sciences, Zhengzhou University, Zhengzhou, China
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Journal of Nanobiotechnology
Fusion exosomes improve the antitumor effect of sorafenib by reversing tumor cell stemness
- 1 October 2026
- Published by Springer Nature in Journal of Nanobiotechnology
Open AccessFusion exosomes improve the antitumor effect of sorafenib by reversing tumor cell stemness
- Open Access
- 9 May 2026
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 15 (5) , e70292
In Situ Engineered “Cascade‐Amplified” Drug‐Loaded Vesicles for Enhanced Cancer Stem Cell Therapy
Cancer stem cells (CSCs) characterized by the capacity of self‐renewal and drug resistance, are a major cause of tumour recurrence and metastasis. However, CSCs are mainly localized in the deep and hypoxic regions of the tumour microenvironment that hinder drug penetration. Furthermore, their overexpression of the CD24/Siglec10 immune checkpoint axis markedly suppresses immune clearance, severely limiting the efficacy of current therapeutic strategies. To address this challenge, this study developed an in situ engineered “cascade‐amplified” drug‐loaded vesicle delivery system, aiming to achieve deep drug delivery into CSC‐enriched regions and enhance anti‐tumour immune responses. Based on a biomimetic “core‐shell” nanoplatform (siXkr8/Dox@PMLC), this system initiates a cascade within the TME where Doxorubicin (Dox) induces tumour cells to generate drug‐loaded apoptotic bodies (ApoBDs). These ApoBDs serve as primary vesicles that, upon uptake by adjacent tumour cells, trigger secondary apoptosis, establishing a “cascade‐amplified” cycle of enhanced drug delivery. Meanwhile, the silencing of the phospholipid scramblase Xkr8 via siRNA inhibits phosphatidylserine (PS) exposure on the surface of ApoBDs, thereby preventing their recognition and clearance by M2‐type macrophages and facilitating immune phenotype remodelling. Furthermore, through targeted blockade of the CD24/Siglec‐10 immune axis, the nanoplatform enhances macrophage‐mediated phagocytosis of CSCs. In summary, this strategy achieves deep eradication of CSCs and synergistically enhances anti‐tumour immunotherapy, demonstrating significant translational potential.
- 9 May 2026
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 15 (5) , e70292
Open AccessIn Situ Engineered “Cascade‐Amplified” Drug‐Loaded Vesicles for Enhanced Cancer Stem Cell Therapy
Cancer stem cells (CSCs) characterized by the capacity of self‐renewal and drug resistance, are a major cause of tumour recurrence and metastasis. However, CSCs are mainly localized in the deep and hypoxic regions of the tumour microenvironment that hinder drug penetration. Furthermore, their overexpression of the CD24/Siglec10 immune checkpoint axis markedly suppresses immune clearance, severely limiting the efficacy of current therapeutic strategies. To address this challenge, this study developed an in situ engineered “cascade‐amplified” drug‐loaded vesicle delivery system, aiming to achieve deep drug delivery into CSC‐enriched regions and enhance anti‐tumour immune responses. Based on a biomimetic “core‐shell” nanoplatform (siXkr8/Dox@PMLC), this system initiates a cascade within the TME where Doxorubicin (Dox) induces tumour cells to generate drug‐loaded apoptotic bodies (ApoBDs). These ApoBDs serve as primary vesicles that, upon uptake by adjacent tumour cells, trigger secondary apoptosis, establishing a “cascade‐amplified” cycle of enhanced drug delivery. Meanwhile, the silencing of the phospholipid scramblase Xkr8 via siRNA inhibits phosphatidylserine (PS) exposure on the surface of ApoBDs, thereby preventing their recognition and clearance by M2‐type macrophages and facilitating immune phenotype remodelling. Furthermore, through targeted blockade of the CD24/Siglec‐10 immune axis, the nanoplatform enhances macrophage‐mediated phagocytosis of CSCs. In summary, this strategy achieves deep eradication of CSCs and synergistically enhances anti‐tumour immunotherapy, demonstrating significant translational potential.
- 7 April 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 265, 115691
Ultrasound-driven nanotechnologies to overcome cancer immunotherapy resistance: From antigen presentation to metabolic rewiring
- 7 April 2026
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 265, 115691
Ultrasound-driven nanotechnologies to overcome cancer immunotherapy resistance: From antigen presentation to metabolic rewiring
- Open Access
- 5 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Biosynthetic OMVs with endogenous GM-CSF loading for ultrasound-triggered in situ cancer vaccination
Impaired dendritic cell (DC) recruitment, maturation, and antigen presentation within the immunosuppressive tumor microenvironment (TME) critically limit t
- 5 February 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessBiosynthetic OMVs with endogenous GM-CSF loading for ultrasound-triggered in situ cancer vaccination
Impaired dendritic cell (DC) recruitment, maturation, and antigen presentation within the immunosuppressive tumor microenvironment (TME) critically limit t
- Open Access
- 3 November 2025
- Published by Wiley in Advanced Science
- Vol. 13 (4) , e08632
In Situ Engineering of Tumor Cells as Self‐Sustaining cDC1 Programming Factories for Effective Cancer Immunotherapy
Conventional type 1 dendritic cells (cDC1s) play a crucial role in initiating and regulating antitumor immunity. However, the insufficient infiltration and dysfunctional state of these cells within the tumor microenvironment hinder antitumor immune response. A tumor‐derived extracellular vesicle (EV), termed AS16‐EL@MPLA/p‐FX, is designed to engineer tumor cells into cDC1 programming factories. The EV lumen carries a plasmid encoding XCL1 and FLT3L. Leveraging the prolonged circulation time and homotypic targeting properties of tumor‐derived EV, AS16‐EL@MPLA/p‐FX demonstrates enhanced tumor‐selective accumulation and efficient cellular internalization. Following uptake, tumor cells are reprogrammed into in situ cytokine factories that continuously secrete XCL1 and FLT3L, which effectively recruit and differentiate cDC1s within the tumor microenvironment. Simultaneously, MPLA embedded in the EV membrane is released locally and activates the newly accumulated cDC1s through the TLR4 pathway. Furthermore, an AS16 peptide is tethered to the EV surface via a matrix metalloproteinase‐2–cleavable linker. The enzymatic release of AS16 disrupts the VEGF–NRP1 interaction, preventing cDC1 exhaustion. The engineered EV, AS16‐EL@MPLA/p‐FX, exhibited remarkable tumor‐targeting capabilities, promoting the recruitment, differentiation, and activation of cDC1s. This innovative approach not only significantly inhibited tumor growth but also triggered a robust immune memory response, safeguarding against tumor metastasis and recurrence.
- 3 November 2025
- Published by Wiley in Advanced Science
- Vol. 13 (4) , e08632
Open AccessIn Situ Engineering of Tumor Cells as Self‐Sustaining cDC1 Programming Factories for Effective Cancer Immunotherapy
Conventional type 1 dendritic cells (cDC1s) play a crucial role in initiating and regulating antitumor immunity. However, the insufficient infiltration and dysfunctional state of these cells within the tumor microenvironment hinder antitumor immune response. A tumor‐derived extracellular vesicle (EV), termed AS16‐EL@MPLA/p‐FX, is designed to engineer tumor cells into cDC1 programming factories. The EV lumen carries a plasmid encoding XCL1 and FLT3L. Leveraging the prolonged circulation time and homotypic targeting properties of tumor‐derived EV, AS16‐EL@MPLA/p‐FX demonstrates enhanced tumor‐selective accumulation and efficient cellular internalization. Following uptake, tumor cells are reprogrammed into in situ cytokine factories that continuously secrete XCL1 and FLT3L, which effectively recruit and differentiate cDC1s within the tumor microenvironment. Simultaneously, MPLA embedded in the EV membrane is released locally and activates the newly accumulated cDC1s through the TLR4 pathway. Furthermore, an AS16 peptide is tethered to the EV surface via a matrix metalloproteinase‐2–cleavable linker. The enzymatic release of AS16 disrupts the VEGF–NRP1 interaction, preventing cDC1 exhaustion. The engineered EV, AS16‐EL@MPLA/p‐FX, exhibited remarkable tumor‐targeting capabilities, promoting the recruitment, differentiation, and activation of cDC1s. This innovative approach not only significantly inhibited tumor growth but also triggered a robust immune memory response, safeguarding against tumor metastasis and recurrence.
- 5 July 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 385, 114001
Enhancing antigen presentation in cancer stem cells via peptide-based nanoparticles for effective immunotherapy
- 5 July 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 385, 114001
Enhancing antigen presentation in cancer stem cells via peptide-based nanoparticles for effective immunotherapy
- 25 January 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 367, 61-75
Biomimetic-gasdermin-protein-expressing nanoplatform mediates tumor-specific pyroptosis for cancer immunotherapy
- 25 January 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 367, 61-75
Biomimetic-gasdermin-protein-expressing nanoplatform mediates tumor-specific pyroptosis for cancer immunotherapy